Abstract Purpose of Review Immunotherapy has emerged as a promising cancer treatment;
however, success in only select clinical indications underscores the need for novel …

Cancer receives enduring international attention due to its extremely high morbidity and
mortality. Immunotherapy, which is generally expected to overcome the limits of traditional …

Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a
popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed …

Listeria monocytogenes is a facultative intracellular gram‐positive bacterium that naturally
infects professional antigen presenting cells (APC) to target antigens to both class I and …

The promise of tumor immunotherapy to significantly improve survival in patients who are
refractory to long-standing therapies, such as chemotherapy and radiation, is now being …

The efficacy and potency of Listeria monocytogenes (LM)-based cancer vaccines are
intricately influenced by the dynamic interplay between the host and pathogen. LM has …

For decades Listeria monocytogenes has been used as a model of host–disease
immunology, and a considerable body of knowledge has been amassed regarding the …

Introduction: The development of an effective therapeutic vaccine to induce cancer-specific
immunity remains problematic. Recently, a species of intracellular pathogen known as …

For over a century, inactivated or attenuated bacteria have been employed in the clinic as
immunotherapies to treat cancer, starting with the Coley's vaccines in the 19th century and …

Cancer is a wide group of diseases, which was responsible for 9.6 million deaths in 2018.
Cancer immunotherapies have become a reality, with the first approval for sipuleucel-T for …